Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-17A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-17A Recombinant Homodimer Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW 31 kDa (disulfide-linked dimer). Native cysteine-knot fold. |
View IL-17A Products |
| Antigen Variant | IL-17F Recombinant Protein Heterodimer partner. High purity (>95%), Sequence Verified. |
View IL-17F Products |
| Gene Delivery | IL-17A Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and secreted expression studies. |
View IL-17A Products |
| Benchmark Ab | Anti-IL-17A (Sequence of Secukinumab) Recombinant positive control, IgG1/kappa. Sequence verified via mass spec. |
View IL-17A Products |
| Benchmark Ab (Alt) | Anti-IL-17A (Sequence of Ixekizumab) Recombinant positive control for comparative binding studies. |
View IL-17A Products |
| Validator | IL-17A siRNA Set For knockdown verification and specificity controls. |
View IL-17A Products |
| Receptor Target | IL-17RA Co-receptor for signal transduction. Required for cell-based functional assays. |
View IL-17RA Products |
| Receptor Target | IL-17RC Essential co-receptor subunit. Validates heterodimeric signaling complexes. |
View IL-17RC Products |
Critical Assay Challenges and TarMart Advantages:
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cyno/Mouse Eval | Human/Mouse/Cynomolgus IL-17A ortholog proteins with >95% purity. Critical for preclinical translation. |
| Subfamily counter screening | IL-17F, IL-17B, IL-17C homolog panel proteins strictly sequence verified. |
| Heterodimer Disruption (IL-17A/F) | IL-17A and IL-17F Homodimer proteins available with matched lots for heterodimer competition assays. Sequence Verified. |
| Receptor Selectivity (RA vs RC) | IL-17RA and IL-17RC recombinant ECD proteins for binary complex formation studies. |
| Lack of Controls | Clinical Benchmark Antibodies (Secukinumab/Ixekizumab Biosimilars) included for direct comparison. |
| False Positives | Validated siRNA included for specificity checks in functional rescue experiments. |
Live IL-17A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-17A therapeutics is intensifying, with major players shifting focus from traditional mAbs to next-generation bispecifics (e.g., targeting both IL-17A and IL-17F) and nanobodies. As first-generation therapies (Secukinumab, Ixekizumab) mature and dominate the psoriasis and ankylosing spondylitis markets, the next wave of R&D is targeting enhanced tissue penetration, improved subcutaneous high-concentration formulations, and dual-pathway blockade to overcome incomplete responses. The market is also seeing increasing demand for biosimilars to address cost and access.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Anti-IL-17A mAb | Novartis, Eli Lilly, Biocad | Psoriasis, PsA, AS | High-Affinity Binding Assay (Need high-purity homodimer proteins) |
| Anti-IL-17A/F Bispecific | UCB (Bimekizumab) | Psoriasis, HS, PsA | Heterodimer Disruption Assay (Need IL-17A + IL-17F proteins) |
| Anti-IL-17RA Receptor Blocker | Bausch/Kyowa Kirin | Psoriasis | Receptor Blocking Assay (Need IL-17RA ECD protein) |
| Small Molecule / Oral Peptides (e.g., RORγt inhibitors) | Dice Therapeutics, Sanofi, Various | Autoimmune Diseases, IBD, RA | Selectivity Assay (Need structural integrity & receptor panels); Functional Cell Lines (Need Lentivirus for IL-17RA/RC stable cells) |
Note: This table consolidates the modalities from both candidate sources, including monoclonal antibodies, bispecifics, receptor blockers, and small molecules targeting the IL-17 pathway.